High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects
Open accessThe DOI matches its Crossref record; 45 of the 47 references it cites were found in a registry or an index.
Abstract
CRISPR-Cas9 nucleases are widely used for genome editing but can induce unwanted off-target mutations. Existing strategies for reducing genome-wide off-target effects of the widely used Streptococcus pyogenes Cas9 (SpCas9) are imperfect, possessing only partial or unproven efficacies and other limitations that constrain their use. Here we describe SpCas9-HF1, a high-fidelity variant harbouring alterations designed to reduce non-specific DNA contacts. SpCas9-HF1 retains on-target activities comparable to wild-type SpCas9 with >85% of single-guide RNAs (sgRNAs) tested in human cells. Notably, with sgRNAs targeted to standard non-repetitive sequences, SpCas9-HF1 rendered all or nearly all off-target events undetectable by genome-wide break capture and targeted sequencing methods. Even for atypical, repetitive target sites, the vast majority of off-target mutations induced by wild-type SpCas9 were not detected with SpCas9-HF1. With its exceptional precision, SpCas9-HF1 provides an alternative to wild-type SpCas9 for research and therapeutic applications. More broadly, our results suggest a general strategy for optimizing genome-wide specificities of other CRISPR-RNA-guided nucleases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Precision editing of alleles in a human cell has drastically improved the understanding of genotypic and phenotypic effects in gene therapy due to the lower off-target rates [119,120,121].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [121]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“To address off-target issues, using the CRISPR system in the form of a rRNP and utilizing high-fidelity CRISPR variants can help minimize off-target effects (Kleinstiver et al., 2016).”
From Emerging applications of gene editing technologies for the development of climate-resilient crops (2025) · cites this paper as Kleinstiver et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Kleinstiver et al. developed the high-fidelity SpCas9-HF1, a variant that produced undetectable genome-wide off-target cleavage [134].”
From CRISPR-Cas: Converting A Bacterial Defence Mechanism into A State-of-the-Art Genetic Manipulation Tool (2019) · cites this paper as [134]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In addition, a series of optimized mutations in SpCas9 have greatly improved the editing specificity of Cas9 variants without substantially attenuating the editing activity.”
From Machine learning-based prediction models to guide the selection of Cas9 variants for efficient gene editing (2024) · cites this paper as [19]
The cited source says what the claim attributes to it.
In the citing paper
“Some active gRNAs for SpCas9-WT showed very low editing ability in SpCas9 variants.”
From Machine learning-based prediction models to guide the selection of Cas9 variants for efficient gene editing (2024) · cites this paper as [19]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kearse, M., Moir, R., Wilson, A., Stones-Havas, S., Cheung, M., Sturrock, S., Buxton, S., Cooper, A., Markowitz, S., Duran, C., et al. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts199 · Cited by 20,027
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System
Zetsche, B., Gootenberg, J. S., Abudayyeh, O. O., Slaymaker, I. M., Makarova, K. S., Essletzbichler, P., Volz, S. E., Joung, J., van der Oost, J., Regev, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.038 · Cited by 4,761
Self-citationDNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299
High-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292
Self-citation
Cited by
Items 401–500 of 1,017
Off-Target Editing by CRISPR-Guided DNA Base Editors
Park, S., & Beal, P. A. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00573 · Cited by 97
Reverse-genetics studies of lncRNAs—what we have learnt and paths forward
Gao, F., Cai, Y., Kapranov, P., & Xu, D. (2020) · Genome biology · doi:10.1186/s13059-020-01994-5 · Cited by 109
“While the authors suggested that CRISPRi had the fewest numbers of the off-target effects, consistent with the currently prevalent notion that the CRISPR/Cas9 technology in general has high precision and fidelity [168], growing evidence suggests that the off-target effects in this system are also nonnegligible [169–17…”
BackgroundVision rescue via unconstrained in vivo prime editing in degenerating neural retinas
Qin, H., Zhang, W., Zhang, S., Feng, Y., Xu, W., Qi, J., Zhang, Q., Xu, C., Liu, S., Zhang, J., et al. (2023) · Journal of Experimental Medicine · doi:10.1084/jem.20220776 · Cited by 82
Discovery of Diverse CRISPR-Cas Systems and Expansion of the Genome Engineering Toolbox
Koonin, E. V., Gootenberg, J. S., & Abudayyeh, O. O. (2023) · Biochemistry · doi:10.1021/acs.biochem.3c00159 · Cited by 103
Gene therapy for cystic fibrosis: new tools for precision medicine
Lee, J. A., Cho, A., Huang, E. N., Xu, Y., Quach, H., Hu, J., & Wong, A. P. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-03099-4 · Cited by 104
Optimization of genome editing through CRISPR-Cas9 engineering
Zhang, J.-H., Adikaram, P. R., Pandey, M., Genis, A., & Simonds, W. F. (2016) · Bioengineered · doi:10.1080/21655979.2016.1189039 · Cited by 103
Cress, B. F., Jones, J. A., Kim, D. C., Leitz, Q. D., Englaender, J. A., Collins, S. M., Linhardt, R. J., & Koffas, M. A. G. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw231 · Cited by 94
Teixeira, M., Py, B. F., Bosc, C., Laubreton, D., Moutin, M., Marvel, J., Flamant, F., & Markossian, S. (2018) · Scientific Reports · doi:10.1038/s41598-017-18826-5 · Cited by 104
Generalizable sgRNA design for improved CRISPR/Cas9 editing efficiency
Hiranniramol, K., Chen, Y., Liu, W., & Wang, X. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa041 · Cited by 89
CRISPR-Cas9 library screening approach for anti-cancer drug discovery: overview and perspectives
Chan, Y.-T., Lu, Y., Wu, J., Zhang, C., Tan, H., Bian, Z., Wang, N., & Feng, Y. (2022) · Theranostics · doi:10.7150/thno.71144 · Cited by 105
CRISPR–Cas9 Gene Editing: Curing Genetic Diseases by Inherited Epigenetic Modifications
Kolanu, N. D. (2024) · Global Medical Genetics · doi:10.1055/s-0044-1785234 · Cited by 120
Temperature effect on CRISPR-Cas9 mediated genome editing
Xiang, G., Zhang, X., An, C., Cheng, C., & Wang, H. (2017) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2017.03.004 · Cited by 100
“S7), the specificity can be improved by designing sgRNAs with minimal potential off-targets or using Cas9 variants with higher fidelity (Kleinstiver et al., 2016; Slaymaker et al., 2016).”
BackgroundChemical and Biophysical Modulation of Cas9 for Tunable Genome Engineering
Nuñez, J. K., Harrington, L. B., & Doudna, J. A. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b01019 · Cited by 92
CRISPR library designer (CLD): software for multispecies design of single guide RNA libraries
Heigwer, F., Zhan, T., Breinig, M., Winter, J., Brügemann, D., Leible, S., & Boutros, M. (2016) · Genome Biology · doi:10.1186/s13059-016-0915-2 · Cited by 91
In trans paired nicking triggers seamless genome editing without double-stranded DNA cutting
Chen, X., Janssen, J. M., Liu, J., Maggio, I., ‘t Jong, A. E. J., Mikkers, H. M. M., & Gonçalves, M. A. F. V. (2017) · Nature Communications · doi:10.1038/s41467-017-00687-1 · Cited by 91
Qian, X., Li, X., Tan, L., Lee, J.-H., Xia, Y., Cai, Q., Zheng, Y., Wang, H., Lorenzi, P. L., & Lu, Z. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0712 · Cited by 89
Chen, Y., Dolt, K. S., Kriek, M., BAKER, T. S., Downey, P. M., Drummond, N. J., Canham, M. A., Natalwala, A., Rosser, S. J., & Kunath, T. (2018) · European Journal of Neuroscience · doi:10.1111/ejn.14286 · Cited by 97
“The use of Cas9 nickase technology (Ran et al., 2013), or next- generation Cas9 enzymes (Kleinstiver et al., 2016), have significantly reduced or eliminated offtarget disruption of the genome and dramatically improved the safety profile of genome- engineered cells for clinical applications.”
BackgroundPlant Virus Vectors 3.0: Transitioning into Synthetic Genomics
Cody, W. B., & Scholthof, H. B. (2019) · Annual Review of Phytopathology · doi:10.1146/annurev-phyto-082718-100301 · Cited by 94
Cas9, Cpf1 and C2c1/2/3―What's next?
Nakade, S., Yamamoto, T., & Sakuma, T. (2017) · Bioengineered · doi:10.1080/21655979.2017.1282018 · Cited by 90
Recent advancements in reducing the off-target effect of CRISPR/Cas9 genome editing
Asmamaw Mengstie, M., Teshome Azezew, M., Asmamaw Dejenie, T., Teshome, A. A., Tadele Admasu, F., Behaile Teklemariam, A., Tilahun Mulu, A., Mekonnen Agidew, M., Adugna, D. G., Geremew, H., et al. (2024) · Biologics: Targets and Therapy · doi:10.2147/btt.s429411 · Cited by 91
Genome editing in cardiovascular diseases
Strong, A., & Musunuru, K. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.139 · Cited by 96
Effective gene editing by high-fidelity base editor 2 in mouse zygotes
Liang, P., Sun, H., Sun, Y., Zhang, X., Xie, X., Zhang, J., Zhang, Z., Chen, Y., Ding, C., Xiong, Y., et al. (2017) · Protein & Cell · doi:10.1007/s13238-017-0418-2 · Cited by 89
Genome Editing for Sustainable Crop Improvement and Mitigation of Biotic and Abiotic Stresses
Hamdan, M. F., Karlson, C. K. S., Teoh, E. Y., Lau, S.-E., & Tan, B. C. (2022) · Plants · doi:10.3390/plants11192625 · Cited by 119
Integrated design, execution, and analysis of arrayed and pooled CRISPR genome-editing experiments
Canver, M. C., Haeussler, M., Bauer, D. E., Orkin, S. H., Sanjana, N. E., Shalem, O., Yuan, G.-C., Zhang, F., Concordet, J.-P., & Pinello, L. (2018) · Nature Protocols · doi:10.1038/nprot.2018.005 · Cited by 85
Höijer, I., Tsai, Y., Clark, T. A., Kotturi, P., Dahl, N., Stattin, E., Bondeson, M.-L., Feuk, L., Gyllensten, U. B., & Ameur, A. (2018) · Human Mutation · doi:10.1002/humu.23580 · Cited by 97
“Also, it would be interesting to evaluate highfidelity Cas9 enzymes that have proven to decrease off-target effects while retaining on-target activity (Kleinstiver et al., 2016).”
BackgroundTranscriptional regulation with CRISPR-Cas9: principles, advances, and applications
Didovyk, A., Borek, B., Tsimring, L., & Hasty, J. (2016) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2016.06.003 · Cited by 90
Design of highly functional genome editors by modeling the universe of CRISPR-Cas sequences
Ruffolo, J. A., Nayfach, S., Gallagher, J., Bhatnagar, A., Beazer, J., Hussain, R., Russ, J., Yip, J., Hill, E., Pacesa, M., et al. (2024) · doi:10.1101/2024.04.22.590591 · Cited by 90
CRISPR/Cas9 for plant genome editing: accomplishments, problems and prospects
Paul, J. W., & Qi, Y. (2016) · Plant Cell Reports · doi:10.1007/s00299-016-1985-z · Cited by 118
Hallmarks of cancer: The CRISPR generation
Moses, C., García‐Bloj, B., Harvey, A. R., & Blancafort, P. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.01.002 · Cited by 106
Kostyushev, D. S., Brezgin, S. A., Kostyusheva, A. P., Zarifyan, D., Goptar, I. A., & Chulanov, V. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03021-8 · Cited by 93
Corte, L. E.-D., Mahmoud, L. M., Moraes, T. D. S., Mou, Z., Grosser, J. W., & Dutt, M. (2019) · Plants · doi:10.3390/plants8120601 · Cited by 102
“similar to the target sequences, unwanted mutations could occur [37,38].”
BackgroundInfluentialOptimized nickase- and nuclease-based prime editing in human and mouse cells
Adikusuma, F., Lushington, C., Arudkumar, J., Godahewa, G. I., Chey, Y. C. J., Gierus, L., Piltz, S., Geiger, A., Jain, Y., Reti, D., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab792 · Cited by 94
“This Cas9 nuclease off-target effect could be reduced by careful design of the gRNAs or by using high-fidelity Cas9 nuclease (8,9,27–29).”
Zhang, X., Jin, H., Huang, X., Chaurasiya, B., Dong, D., Shanley, T. P., & Zhao, Y. (2022) · Cell Reports · doi:10.1016/j.celrep.2021.110196 · Cited by 93
“Thus, with the development of more specific CRISPR systems with reduced off-target effects (Chen et al., 2017; Kleinstiver et al., 2016; Slaymaker et al., 2016) as well as base editors and the prime editing system, this strategy may have great potential for therapeutic genome editing in humans to prevent and treat vas…”
BackgroundKim, J. (2016) · Nature Protocols · doi:10.1038/nprot.2016.104 · Cited by 107
CRISPR/Cas9: Transcending the Reality of Genome Editing
Chira, S., Gulei, D., Hajitou, A., Zimța, A., Cordelier, P., & Berindan‐Neagoe, I. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.04.001 · Cited by 95
Allen, D. G., Rosenberg, M., & Hendel, A. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2020.617910 · Cited by 96
A DNA Origami‐Based Gene Editing System for Efficient Gene Therapy in Vivo
Tang, W., Tong, T., Wang, H., Lu, X., Yang, C., Wu, Y., Wang, Y., Liu, J., & Ding, B. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202315093 · Cited by 93
Genome-wide CRISPR off-target prediction and optimization using RNA-DNA interaction fingerprints
Chen, Q., Chuai, G., Zhang, H., Tang, J., Duan, L., Guan, H., Li, W., Li, W., Wen, J., Zuo, E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42695-4 · Cited by 100
Versatility of chemically synthesized guide RNAs for CRISPR-Cas9 genome editing
Kelley, M. L., Strezoska, Ž., He, K., Vermeulen, A., & Smith, A. V. B. (2016) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2016.06.011 · Cited by 95
Precise genome-wide base editing by the CRISPR Nickase system in yeast
Satomura, A., Nishioka, R., Mori, H., Sato, K., Kuroda, K., & Ueda, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-02013-7 · Cited by 86
Base Editing in Plants: Applications, Challenges, and Future Prospects
Azameti, M. K., & Dauda, W. P. (2021) · Frontiers in Plant Science · doi:10.3389/fpls.2021.664997 · Cited by 88
Sharma, A. K., Nymark, M., Sparstad, T., Bones, A. M., & Winge, P. (2018) · Scientific Reports · doi:10.1038/s41598-018-32342-0 · Cited by 82
Skryabin, B. V., Kummerfeld, D.-M., Gubar, L., Seeger, B., Kaiser, H., Stegemann, A., Roth, J., Meuth, S. G., Pavenstädt, H., Sherwood, J., et al. (2020) · Science Advances · doi:10.1126/sciadv.aax2941 · Cited by 89
Tabassum, J., Ahmad, S., Hussain, B., Mawia, A. M., Zeb, A., & Ju, L. (2021) · Agronomy · doi:10.3390/agronomy11071359 · Cited by 93
“In contrast, Cas9 proteins have been modified for improved target specificity, including eSpCas9 [121], HF-Cas9 [122], HypaCas9 [123], and Sniper Cas9 [124].”
BackgroundDubey, A. K., Gupta, V. K., Kujawska, M., Orive, G., Kim, N., Li, C.-Z., Mishra, Y. K., & Kaushik, A. K. (2022) · Journal of nanostructure in chemistry · doi:10.1007/s40097-022-00472-7 · Cited by 93
“Off-target effects have been reduced using a variety of approaches, including designing a highspecificity Cas9 protein [250, 251].”
BackgroundRNA Interference in the Age of CRISPR: Will CRISPR Interfere with RNAi?
Unniyampurath, U., Pilankatta, R., & Krishnan, M. N. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17030291 · Cited by 100
Katoh, Y., Michisaka, S., Nozaki, S., Funabashi, T., Hirano, T., Takei, R., & Nakayama, K. (2017) · Molecular Biology of the Cell · doi:10.1091/mbc.e17-01-0051 · Cited by 88
Beyond Native Cas9: Manipulating Genomic Information and Function
Mitsunobu, H., Teramoto, J., Nishida, K., & Kondo, A. (2017) · Trends in biotechnology · doi:10.1016/j.tibtech.2017.06.004 · Cited by 88
Llères, D., Moindrot, B., Pathak, R., Piras, V., Matelot, M., Pignard, B., Marchand, A., Poncelet, M., Perrin, A., Tellier, V., et al. (2019) · Genome biology · doi:10.1186/s13059-019-1896-8 · Cited by 94
“The Cas9-VP12 vector [50] (a gift from Keith Joung; #72247, Addgene) was modified by adding T2A-GFP at the C-terminal end and electroporated with the sgRNA vector into JB1 and BJ1 hybrid ES cells using the Amaxa nucleofector procedure (Lonza).”
MethodEngineering Gene Therapy: Advances and Barriers
Shahryari, A., Burtscher, I., Nazari, Z., & Lickert, H. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100040 · Cited by 81
Custom CRISPR–Cas9 PAM variants via scalable engineering and machine learning
Silverstein, R. A., Kim, N., Kroell, A.-S., Walton, R. T., Delano, J., Butcher, R. M., Pacesa, M., Smith, B. K., Christie, K. A., Ha, L. L., et al. (2025) · Nature · doi:10.1038/s41586-025-09021-y · Cited by 73
“…library of SpCas9 variant enzymes using a structure–function-informed approach based on SpCas9 structures 10 and previous engineering efforts 3,14,42,43 , simultaneously mutating six amino acid residues within the SpCas9 PI domain, resulting in a library with theoretical complexity of 64 million…”
Self-citationRevolutionizing CRISPR technology with artificial intelligence
Kim, M., Go, M.-J., Kang, S.-H., Jeong, S.-H., & Lim, K. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01462-9 · Cited by 101
Genomes in Focus: Development and Applications of CRISPR‐Cas9 Imaging Technologies
Knight, S. C., Tjian, R., & Doudna, J. A. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201709201 · Cited by 85
Rescue of high-specificity Cas9 variants using sgRNAs with matched 5’ nucleotides
Kim, S., Bae, T., Hwang, J., & Kim, J.-S. (2017) · Genome Biology · doi:10.1186/s13059-017-1355-3 · Cited by 88
Chen, P., Zhou, J., Wan, Y., Liu, H., Li, Y., Liu, Z., Wang, H., Lei, J., Zhao, K., Zhang, Y., et al. (2020) · Genome biology · doi:10.1186/s13059-020-01989-2 · Cited by 92
Genome editing in crop improvement: Present scenario and future prospects
Miglani, G. S. (2017) · Journal of Crop Improvement · doi:10.1080/15427528.2017.1333192 · Cited by 84
“In another case, the Cas9 structure was also probed to find aa residues that stabilize the target DNA strand and the 5′-end of the gRNA (distal to the PAM) via hydrogen bonding (Kleinstiver et al. 2016).”
BackgroundInsulin fine-tunes self-renewal pathways governing naive pluripotency and extra-embryonic endoderm
Anderson, K. G. V., Hamilton, W. B., Roske, F. V., Azad, A., Knudsen, T. E., Canham, M. A., Forrester, L. M., & Brickman, J. M. (2017) · Nature Cell Biology · doi:10.1038/ncb3617 · Cited by 87
Application and future perspective of CRISPR/Cas9 genome editing in fruit crops
Zhou, J., Li, D., Wang, G., Wang, F., Kunjal, M., Joldersma, D., & Liu, Z. (2019) · Journal of Integrative Plant Biology · doi:10.1111/jipb.12793 · Cited by 95
“Another way to reduce off-target is to use high fidelity Cas9 nucleases such as the “enhanced specificity” SpCas9 (eSpCas9) (Slaymaker et al. 2016), high-fidelity SpCas9-HF1 (Kleinstiver et al. 2016), hyperaccurate Cas9 (Hypacas9) (Chen et al. 2017), and xCas9 (Hu et al. 2018).”
BackgroundCRISPR/Cas9 system in breast cancer therapy: advancement, limitations and future scope
Karn, V., Sandhya, S., Hsu, W., Parashar, D., Singh, H. N., Jha, N. K., Gupta, S. K., Dubey, N. K., & Kumar, S. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02654-3 · Cited by 90
CRISPR/Cas9 Technology and Its Utility for Crop Improvement
Liu, H., Chen, W., Li, Y., Sun, L., Chai, Y., Chen, H., Nie, H., & Huang, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810442 · Cited by 93
Regenerating human epithelia with cultured stem cells: feeder cells, organoids and beyond
Hynds, R. E., Bonfanti, P., & Janes, S. M. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201708213 · Cited by 86
“…application of gene editing technologies, such as adeno-associated viral vectors (AAVs; Melo et al, 2014) or high-fidelity CRISPR-Cas9 systems (Kleinstiver et al, 2016), could be safe and effective means to generate gene-corrected, clonally derived CEAs for transplantation but are not yet in…”
MethodCRISPR-Based Gene Drives for Pest Control
McFarlane, G. R., Whitelaw, B., & Lillico, S. G. (2018) · Trends in biotechnology · doi:10.1016/j.tibtech.2017.10.001 · Cited by 93
CRISPR-mediated genome editing and human diseases
Cai, L., Fisher, A. L., Huang, H., & Xie, Z. (2016) · Genes & Diseases · doi:10.1016/j.gendis.2016.07.003 · Cited by 83
Genotyping genome‐edited mutations in plants using CRISPR ribonucleoprotein complexes
Liang, Z., Chen, K., Yan, Y., Zhang, Y., & Gao, C. (2018) · Plant Biotechnology Journal · doi:10.1111/pbi.12938 · Cited by 90
“1, SpCas9-HF1 and HypaCas9, have been rationally engineered to increase the specificity of editing (Chen et al., 2017a; Kleinstiver et al., 2016; Slaymaker et al., 2016).”
BackgroundApplication of CRISPR/Cas9 gene editing technique in the study of cancer treatment
Jiang, C., Meng, L., Yang, B., & Luo, X. (2019) · Clinical Genetics · doi:10.1111/cge.13589 · Cited by 91
Toward the correction of muscular dystrophy by gene editing
Olson, E. N. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2004840117 · Cited by 87
Expanding the plant genome editing toolbox with recently developed CRISPR–Cas systems
Wada, N., Osakabe, K., & Osakabe, Y. (2022) · PLANT PHYSIOLOGY · doi:10.1093/plphys/kiac027 · Cited by 88
Guide RNA engineering for versatile Cas9 functionality
Nowak, C. M., Lawson, S., Zerez, M., & Bleris, L. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw908 · Cited by 86
CRISPR–Cas9 a boon or bane: the bumpy road ahead to cancer therapeutics
Ghosh, D., Venkataramani, P., Nandi, S., & Bhattacharjee, S. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0726-0 · Cited by 76
Lopes, R., & Prasad, M. K. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1339189 · Cited by 82
Kim, H., Choi, J., & Won, K. (2020) · BMC Plant Biology · doi:10.1186/s12870-020-02665-0 · Cited by 87
CRISPR Therapeutics for Duchenne Muscular Dystrophy
Erkut, E. J. N., & Yokota, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031832 · Cited by 96
“These modified Cas9 enzymes include eSpCas9(1.1) [39], SpCas9-HF1 [40], HypaCas9 [41], HeFSpCas9s [42], evoCas9 [43], xCas9 [44], HiFi Cas9 [45], Sniper-Cas9 [46], and SpCas9-NG [47].”
BackgroundInfluentialEnhancement of specialized metabolites using CRISPR/Cas gene editing technology in medicinal plants
Das, S., Kwon, M., & Kim, J. (2024) · Frontiers in Plant Science · doi:10.3389/fpls.2024.1279738 · Cited by 88
Shen, C., Hsu, M., Chang, C.-W., Lin, M., Hwu, J. R., Tu, Y., & Hu, Y. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky1165 · Cited by 86
“Although the engineered Cas9 (e.g. eSpCas9 (37) or Cas9-HF1 (38)) effectively reduces the off-target effects, the cognate PAM sequence (NGG) for Cas9 may not be present in the close proximity of the desired sequence to edit.”
BackgroundMethodConformational states of Cas9-sgRNA-DNA ternary complex in the presence of magnesium
Zhu, X. Q., Clarke, R., Puppala, A. K., Chittori, S., Merk, A., Merrill, B. J., Simonović, M., & Subramaniam, S. (2019) · Worldwide Protein Data Bank · doi:10.2210/pdb6o0z/pdb · Cited by 82
Assou, S., Bouckenheimer, J., & De Vos, J. (2018) · Stem Cells · doi:10.1002/stem.2797 · Cited by 81
A Self-restricted CRISPR System to Reduce Off-target Effects
Chen, Y., Liu, X., Zhang, Y., Wang, H., Ying, H., Liu, M., Li, D., Lui, K. O., & Ding, Q. (2016) · Molecular Therapy · doi:10.1038/mt.2016.172 · Cited by 81
Raveux, A., Vandormael‐Pournin, S., & Cohen‐Tannoudji, M. (2017) · Scientific Reports · doi:10.1038/srep42661 · Cited by 84
Application of Genetically Engineered Pigs in Biomedical Research
Hryhorowicz, M., Lipiński, D., Hryhorowicz, S., Nowak, A., Ryczek, N., & Zeyland, J. (2020) · Genes · doi:10.3390/genes11060670 · Cited by 103
“Protein Cas9 properties can be modified, or their lifespan can be changed [112,113].”
BackgroundDevelopment and Application of CRISPR/Cas in Microbial Biotechnology
Ding, W., Zhang, Y., & Shi, S. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00711 · Cited by 87
Detect and destroy: CRISPR-based technologies for the response against viruses
Freije, C. A., & Sabeti, P. C. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.04.003 · Cited by 84
Song, Z., Tao, Y., Liu, Y., & Li, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1444437 · Cited by 89
CRISPR system in filamentous fungi: Current achievements and future directions
Deng, H., Gao, R., Liao, X., & Cai, Y. (2017) · Gene · doi:10.1016/j.gene.2017.06.019 · Cited by 89
FACS-Assisted CRISPR-Cas9 Genome Editing Facilitates Parkinson's Disease Modeling
Arias, J., Jarazo, J., Qing, X., Walter, J., Gomez‐Giro, G., Nickels, S., Zaehres, H., Schöler, H. R., & Schwamborn, J. C. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.08.026 · Cited by 89
“Furthermore, Cas9 specificity has been improved with high-fidelity variants (Kleinstiver et al., 2016).”
BackgroundNew traits in crops produced by genome editing techniques based on deletions
van de Wiel, C. C. M., Schaart, J. G., Lotz, L. A. P., & Smulders, M. J. M. (2017) · Plant Biotechnology Reports · doi:10.1007/s11816-017-0425-z · Cited by 80
He, Z., Zhang, T., Jiang, L., Zhou, M., Wu, D., Mei, J., & Cheng, Y. (2018) · Bioscience Reports · doi:10.1042/bsr20180742 · Cited by 79
Rayner, E., Durin, M.-A., Thomas, R., Moralli, D., O'Cathail, S. M., Tomlinson, I., Green, C. M., & Lewis, A. (2019) · The CRISPR Journal · doi:10.1089/crispr.2019.0006 · Cited by 74
“Re-engineering of the Cas9 protein and modifying the sgRNA scaffold have also been shown to increase target specificity.(19,20) We expect that”
Synthetic multi-layer nanoparticles for CRISPR-Cas9 genome editing
Tang, H., Zhao, X., & Jiang, X. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.03.001 · Cited by 83
“To reduce the off-target effect and improve the specificity of CRISPR-Cas9 system, a series of strategies have been established, for example: (1) reduce and limit the retention time of Cas9 protein inside cells [23, 24]; (2) decrease the feeding concentration of Cas9 protein [25]; (3) activate Cas9 specifically by exo…”
BackgroundLi, C., Zong, Y., Jin, S., Zhu, H., Lin, D., Li, S., Qiu, J.-L., Wang, Y., & Gao, C. (2020) · Genome Biology · doi:10.1186/s13059-020-02051-x · Cited by 79
CRISPR/Cas: From Tumor Gene Editing to T Cell-Based Immunotherapy of Cancer
Azangou‐Khyavy, M., Ghasemi, M., Khanali, J., Boroomand-Saboor, M., Jamalkhah, M., Soleimani, M., & Kiani, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02062 · Cited by 86
CRISPR/Cas-Based Modifications for Therapeutic Applications: A Review
Bharathkumar, N., Abraham, S., Meera, P., Aksah, S., Muthu, K., Saravanan, K. M., & Anand, T. (2021) · Molecular Biotechnology · doi:10.1007/s12033-021-00422-8 · Cited by 96
Programmable DNA looping using engineered bivalent dCas9 complexes
Hao, N., Shearwin, K. E., & Dodd, I. B. (2017) · Nature Communications · doi:10.1038/s41467-017-01873-x · Cited by 77
Applications of CRISPR Genome Engineering in Cell Biology
Wang, F., & Qi, L. S. (2016) · Trends in Cell Biology · doi:10.1016/j.tcb.2016.08.004 · Cited by 86
“pyogenes Cas9 variants with improved specificity [112,113].”
Dürr, J., Papareddy, R. K., Nakajima, K., & Gutierrez‐Marcos, J. (2018) · Scientific Reports · doi:10.1038/s41598-018-22667-1 · Cited by 83
gRNA validation for wheat genome editing with the CRISPR-Cas9 system
Arndell, T., Sharma, N., Langridge, P., Baumann, U., Watson-Haigh, N. S., & Whitford, R. (2019) · BMC Biotechnology · doi:10.1186/s12896-019-0565-z · Cited by 77
The clinical potential of gene editing as a tool to engineer cell‐based therapeutics
Ashmore‐Harris, C., & Fruhwirth, G. O. (2020) · Clinical and Translational Medicine · doi:10.1186/s40169-020-0268-z · Cited by 79
Ke, Y., Ghalandari, B., Huang, S., Li, S., Huang, C., Zhi, X., Cui, D., & Ding, X. (2022) · Chemical Science · doi:10.1039/d1sc06832f · Cited by 79
Antiviral Goes Viral: Harnessing CRISPR/Cas9 to Combat Viruses in Humans
Soppe, J. A., & Lebbink, R. J. (2017) · Trends in Microbiology · doi:10.1016/j.tim.2017.04.005 · Cited by 83
The initiation, propagation and dynamics of CRISPR-SpyCas9 R-loop complex
Zeng, Y., Cui, Y., Zhang, Y., Zhang, Y., Liang, M., Chen, H., Lan, J., Song, G., & Lou, J. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx1117 · Cited by 81
CRISPR-Cas9 genome engineering: Treating inherited retinal degeneration
Burnight, E. R., Giacalone, J. C., Cooke, J. A., Thompson, J. R., Bohrer, L. R., Chirco, K. R., Drack, A. V., Fingert, J. H., Worthington, K. S., Wiley, L. A., et al. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.03.003 · Cited by 74
Metadata
- Authors
- Kleinstiver, B. P., Pattanayak, V., Prew, M. S., Tsai, S. Q., Nguyen, N. T., Zheng, Z., & Joung, J. K.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital (US)
- City University of Hong Kong (HK)
- Corresponding author
- Joung, J. Keith
- ORCID
- Venue
- Nature
- Published
- 2016-01-06
- Volume
- 529
- Issue
- 7587
- Pages
- 490-495
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4851738
- OpenAlex
- W2224398381
- Cited by
- 2,673
- References
- 47
- Citations by year
- 2026: 189 · 2025: 221 · 2024: 200 · 2023: 181 · 2022: 267 · 2021: 273 · 2020: 287 · 2019: 284 · 2018: 284 · 2017: 267 · 2016: 215
- FWCI
- 181.19
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute of General Medical Sciences (DP1GM105378, R01GM107427, R01GM088040)
- National Center for Chronic Disease Prevention and Health Promotion (DP1 GM105378)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- CRISPR/Cas9, off-target mutations, Streptococcus pyogenes, single guide RNA, targeted sequencing, genome editing
- MeSH terms
- Base Sequence, DNA, DNA-Binding Proteins, Endonucleases, Genetic Engineering, Humans, Mutation, Protein Binding, RNA, Streptococcus pyogenes, Substrate Specificity, Reproducibility of Results, Genome, Human, Sequence Analysis, DNA, Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR-Cas Systems, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.